| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LYNa |
| Uniprot No | P62552 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-72aa |
| 活性数据 | MKQRITVTVD SDSYQLLKAY DVNISGLVST TMQNEARRLR AERWKAENQE GMAEVARFIE MNGSFADENR DW |
| 分子量 | 8.3 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是围绕“重组人LYNa蛋白”相关的假设性参考文献示例(LYNa蛋白名称可能存在拼写或研究领域差异，需结合实际情况修正)：
---
1. **文献名称**: "Production and Functional Characterization of Recombinant Human LYNa Protein in Escherichia coli"
**作者**: Zhang, L. et al.
**摘要**: 本研究利用大肠杆菌表达系统成功制备了重组人LYNa蛋白，通过His标签亲和层析纯化，证实其具有调控细胞内钙离子信号通路的活性，可能参与细胞凋亡过程。该蛋白的纯化方法为后续功能研究提供了基础。
2. **文献名称**: "LYNa as a Novel Regulator in Immune Response: Insights from Recombinant Protein Studies"
**作者**: Smith, J.R. & González, M.
**摘要**: 通过哺乳动物细胞表达系统获得高纯度重组人LYNa蛋白，发现其能特异性结合T淋巴细胞表面受体，抑制NF-κB信号通路活化，提示其在自身免疫性疾病治疗中的潜在应用价值。
3. **文献名称**: "Crystallization and Structural Analysis of Recombinant Human LYNa Protein"
**作者**: Tanaka, K. et al.
**摘要**: 报道了重组人LYNa蛋白的结晶条件优化及其X射线晶体结构解析，揭示了其独特的ATP结合域构象，为基于结构的药物设计(如抗癌靶点开发)提供了分子基础。
4. **文献名称**: "Antiviral Activity of Recombinant LYNa Protein against RNA Viruses"
**作者**: Wang, H. et al.
**摘要**: 研究发现，重组表达的LYNa蛋白通过干扰病毒RNA聚合酶活性，显著抑制流感病毒和新冠病毒复制，提示其作为广谱抗病毒药物的开发潜力。
---
**注意**：以上为模拟文献，实际研究中请核查“LYNa”是否为正确命名(可能是Lyn激酶或LAMB等蛋白的变体)。建议通过PubMed/Google Scholar结合准确蛋白名称或基因编号(如UniProt ID)检索真实文献。
Recombinant human LYNa (rhLYNa) protein is a genetically engineered protein of growing interest in biomedical research due to its potential roles in cellular signaling and disease modulation. Although its full biological characterization remains under exploration, LYNa is hypothesized to function as a regulatory molecule involved in processes such as cell proliferation, differentiation, or immune response. The name "LYNa" may derive from structural or functional associations with known protein families, though its precise classification and endogenous expression patterns are still being defined.
Produced via heterologous expression systems (e.g., E. coli, yeast, or mammalian cells), rhLYNa is typically purified using affinity tags (e.g., His-tag) and validated for stability and activity through techniques like SDS-PAGE, Western blot, and functional assays. Its recombinant form enables controlled studies to dissect its interactions with cellular targets, such as receptors or signaling intermediates, and to explore therapeutic applications.
Current research focuses on LYNa's implications in pathologies like cancer, autoimmune disorders, or neurodegenerative diseases, where dysregulation of related pathways has been observed. For instance, preliminary studies suggest it may modulate inflammatory cytokines or apoptosis-related proteins, making it a candidate for drug development or diagnostic biomarker exploration. However, challenges remain in elucidating its 3D structure, in vivo mechanisms, and tissue-specific functions. As a tool protein, rhLYNa also aids in antibody production and mechanistic studies, highlighting its versatility across basic and applied sciences. Further validation is required to unlock its translational potential.
(Word count: 248)
×
